Craig-Hallum Maintains Buy on MapLight Therapeutics, Lowers Price Target to $40
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. MPLT | 0.00 |
Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:
MPLT) with a Buy and lowers the price target from $43 to $40.
